Cyclerion Therapeutics, Inc.
CYCN
$3.13
-$0.05-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 17.14% | 840.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.14% | 840.86% | |||
| Cost of Revenue | 49.14% | 521.43% | |||
| Gross Profit | -3.98% | 1,324.32% | |||
| SG&A Expenses | -12.33% | -10.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.96% | 6.57% | |||
| Operating Income | 16.70% | 39.83% | |||
| Income Before Tax | 18.14% | -201.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.14% | -201.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.14% | -201.23% | |||
| EBIT | 16.70% | 39.83% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 30.70% | -186.82% | |||
| Normalized Basic EPS | 30.72% | 43.38% | |||
| EPS Diluted | 30.70% | -186.82% | |||
| Normalized Diluted EPS | 30.72% | 43.38% | |||
| Average Basic Shares Outstanding | 18.17% | 5.01% | |||
| Average Diluted Shares Outstanding | 18.17% | 5.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||